A May MD
Biotech investor
Adam May is a practicing dermatologist who also invests in biotechnology, posting on X as @A_May_MD. Discussing skin-cancer cases in a clinical trial on 3 June 2026 he wrote, "Far be it from me to minimize NMSC (since it is what I treat for a living as a dermatologist)." The Yet Another Value Podcast, which interviewed him in 2026, describes him as a physician and dermatologist who launched a small biotech fund in 2021. His posts deal with clinical trial design and readouts at small- and mid-cap drug developers, most often Abivax, Nektar Therapeutics, Novo Nordisk and Hims & Hers, and he discloses both long and short positions.
Leaderboard rank
Open in leaderboard →| Horizon | 7D | 30D | 90D | 180D | 360D | AVG |
|---|---|---|---|---|---|---|
| Rank | #478 | #972 | #425 | #573 | — | #529 |
| Calls | 36 | 31 | 27 | 20 | 0/10 | 31 |
| Avg return | +0.8% | -7.2% | +1.6% | -12.9% | — | -5.5% |
| vs S&P 500 | +0.3 pp | -8.7 pp | -0.7 pp | -20.0 pp | — | -8.7 pp |
Ticker
Side
Calls
Mentions
First Call
Best call P&L
Status
Chart
Source
Loading
Showing 0 of 25 calls · sorted by mentions
Loading
A May MD has 29 trade ideas tracked on Buzzberg across 25 tickers since January 2026. Win rate 44% across 25 evaluated calls, average return -7.0%. Ranked #972 on Buzzberg's 30-day Authors leaderboard. Most covered: ABVX, NKTR, NVO.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
